Disclosed herein are compositions and methods for increasing visual acuity in patients in need thereof and for treating vascular disorders of the eye.

The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.

The present invention relates to methods for the treatment of a bone fracture or bone defect. The invention discloses the effective use of an anti-gremlin-1 antibody to accelerate the healing and bridging of bone tissue in segmental gap defects; and demonstrates that inhibitors of gremlin-1 activity may provide improved therapies for treating or preventing fracture non-union.

The present invention relates to a novel cloning, expression and refolding process for preparing antibody fragments. More particularly, the present invention relates to a cloning, expression and refolding platform for preparing recombinant humanized (rHu) Ranibizumab.

The present invention relates to a novel cloning, expression and refolding process for preparing antibody fragments. More particularly, the present invention relates to a cloning, expression and refolding platform for preparing recombinant humanized (rHu) Ranibizumab.

Provided herein are isolated antibodies or antibody fragments thereof that immunospecifically bind to platelet factor 4 (PF4). In some embodiments the isolated antibodies or antigen-binding fragments thereof comprise a light chain CDR and framework region comprising SEQ ID NO: 4 and a heavy chain CDR and framework region comprising SEQ ID NO: 10. Also provided herein are methods for treating heparin-induced thrombocytopenia (HIT) and methods for reducing the likelihood that subject will become afflicted with HIT. Further disclosed are uses of the isolated antibodies or antibody fragments in the treatment of HIT or the manufacture of compositions for the treatment of HIT.

Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

Provided herein are methods for predicting whether a cancer patient will respond to treatment with bevacizumab based on determining a level of small extracellular vesicle (sEV)-associated VEGF in the patient. Also provided are methods of treating patients with either bevacizumab or a VEGFR tyrosine kinase inhibitor, a VEGFR neutralizing antibody, or a VEGF ligand trap based on the level of small extracellular vesicle (sEV)-associated VEGF in the patient.

Provided herein are methods for predicting whether a cancer patient will respond to treatment with bevacizumab based on determining a level of small extracellular vesicle (sEV)-associated VEGF in the patient. Also provided are methods of treating patients with either bevacizumab or a VEGFR tyrosine kinase inhibitor, a VEGFR neutralizing antibody, or a VEGF ligand trap based on the level of small extracellular vesicle (sEV)-associated VEGF in the patient.